Table 2_Establishment and characterization of patient-derived mucinous gastric cancer organoids with faithful histopathological features and reproducible drug response patterns.docx

Furthermore, organoid-based drug responses were correlated with the clinical outcomes of eight patients who received oxaliplatin-based adjuvant chemotherapy.</p>Results<p>All MGC organoids faithfully maintained the histological architecture, mucus secretion capability, and biomarker profiles of the parental tumors over serial passages. High-throughput drug sensitivity screening revealed consistent resistance to 5-fluorouracil and oxaliplatin, and marked sensitivity to taxane-based agents, across the MGC panel.

Preliminary clinical correlation in eight patients showed 87.5% concordance between organoid-based predictions and actual chemotherapy outcomes.</p>Conclusion<p>We established and characterized patient-derived MGC organoids from three patients, demonstrating faithful histological and molecular preservation, dynamic mucus secretion, and reproducible drug sensitivity pattern. Preliminary clinical correlation in a small cohort showed promising concordance.

These proof-of-concept findings establish a platform for future precision oncology research in this rare gastric cancer subtype, pending larger prospective validation.</p>